TY  - JOUR

T1  - SOGUG-NEOWIN: A Phase 2, open-label, multi-centre, multi-national interventional trial evaluating the efficacy and safety of Erdafitinib (ERDA) monotherapy and ERDA and Cetrelimab (CET) as neoadjuvant treatment in cisplatin-ineligible patients with Muscle-Invasive Bladder Cancer (MIBC) whose tumours express FGFR gene alterations

JO  - European Urology

UR  - http://dx.doi.org/10.1016/s0302-2838(24)00385-3

PY  - 2024/03/01

AU  - Necchi A

AU  - Hussain SA

AU  - Loriot Y

AU  - de Velasco G

ED  - 

DO  - DOI: 10.1016/s0302-2838(24)00385-3

PB  - Elsevier BV

VL  - 85

SP  - S427

EP  - S427

Y2  - 2024/12/22

ER  -